Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 13110 publications
Detailed I/E report of Resveratrol export analysis US$ 5,400.00

Resveratrol export analysis will help clients understandthe export situation of technical and formulations with exclusive research methods and offer not only the products’export volume, price, time, source / destination countries, specification, application, but alsoinformation on exporters, manufacturers, ...

Jul, 2014
Global Infection Prevention and Control Market 2014-2018 US$ 3,000.00

... by hospitals and various industries. TechNavio's analysts forecast the Global Infection Prevention and Control market will grow at a CAGR of 7.47 percent over the ... detailed analysis of the top four vendors in the Global Infection Prevention and Control market. In addition, the report discusses the major ...

Jul, 2014 107 pages
Research on China Cardiovascular Drugs Industry, 2014-2018 US$ 2,500.00

Research on China Cardiovascular Drugs Industry, 2014-2018 primarily carries on analyses on cardiovascular drugs market in the following aspects: market scale, the ... . In the next ten years, there is a potential for the growth in cardiovascular diseases treatment field. It is predicted that the growth rate will ...

May, 2014 85 pages
Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice (2014 Edition) US$ 1,495.00

... and approval delays eat up your development time and budget. This Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice (2014 Edition) not only provided a comprehensive and thorough knowledge of the latest Chinese regulations on clinical ...

Jul, 2014 191 pages
Zyngenia, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Zyngenia, Inc.’s pipeline products ... drug targets and therapeutic classes in the Zyngenia, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Jul, 2014 24 pages
Venus Remedies Limited - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Venus Remedies Limited’s human therapeutic ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Venus Remedies Limited’s pipeline products Reasons ...

Jul, 2014 23 pages
Phylogica Limited - Product Pipeline Review - 2014 US$ 1,500.00

... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Phylogica Limited’s pipeline products ... areas of focus Identify new drug targets and therapeutic classes in the Phylogica Limited’s R&D portfolio and develop key strategic initiatives to reinforce ...

Jul, 2014 22 pages
Genexine, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Genexine, Inc.’s pipeline products ... drug targets and therapeutic classes in the Genexine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Jul, 2014 32 pages
Ensemble Discovery Corporation - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Ensemble Discovery Corporation’s pipeline products Reasons to ...

Jul, 2014 28 pages
Dong Wha Pharma Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... disease. Scope The report provides brief overview of Dong Wha Pharma Co., Ltd. including business description, key information and facts, and its ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Dong Wha Pharma Co., Ltd.’s pipeline products ...

Jul, 2014 32 pages
OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 US$ 5,995.00

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 SUMMARY Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded ... 2015-2020. Annual cost of therapy (ACOT) and major pipeline vaccine sales in this forecast period are included. Key topics covered ...

Jul, 2014 188 pages
Zolmitriptan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Zoledronic Acid - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Zoledronic Acid indications: Bone damage due to malignancies innovator: Novartis (Zometa) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Ziprasidone - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Vortioxetine - Comprehensive patent search US$ 7,500.00

... , save searches and results THIS REPORT COVERS: International Nonproprietary Name: Vortioxetine indications: Treatment of major depressive disorder and generalised anxiety disorder innovator:Takeda; Lundbeck COUNTRY COVERAGE: The In-depth search contains patents from territories that are individually ...

Jul, 2014
Voriconazole - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Voriconazole indications: Treatment of aspergillosis; serious Candida infections; serious refractory fungal infections. innovator: Pfizer (Vfend) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina ...

Jul, 2014
Vildagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... THIS REPORT COVERS: International Nonproprietary Name: Vildagliptin indications: Treatment of type 2 diabetes mellitus, optionally in combination with Metformin, a sulphonylurea, a thiazolidinedione or Insulin innovator: Novartis (Galvus, Jalra, Icandra, Xiliarx, Zomarist, Eucreas, Sobrea, Galvumet) ...

Jul, 2014
Vilazodone - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Vilazodone indications: Treatment of major depressive disorder innovator: Forest (Viibryd) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Venlafaxine - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Venlafaxine indications: Depression; Generalised anxiety disorder innovator: Wyeth (Effexor, Efexor) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Vardenafil - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Vandetanib - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results THIS REPORT COVERS: International Nonproprietary Name: Vandetanib indications: Treatment of medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease innovator: IPR (Caprelsa), Astrazeneca (Caprelsa, Zactima) COUNTRY COVERAGE: Albania Australia Austria ...

Jul, 2014
Vandetanib - Comprehensive patent search US$ 9,300.00

... and results THIS REPORT COVERS: International Nonproprietary Name: Vandetanib indications: Treatment of medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease innovator:IPR (Caprelsa), Astrazeneca (Caprelsa, Zactima) COUNTRY COVERAGE: The In-depth search contains ...

Jul, 2014
Valsartan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Valsartan indications: Hypertension; Hypertension (with HCTZ) innovator: Novartis (Diovan, Diovan HCT, Co-Diovan) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Valganciclovir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... : Valganciclovir indications: Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS; Prophylaxis of CMV infection/disease after solid organ transplant. innovator: Roche ...

Jul, 2014
Topiramate - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results THIS REPORT COVERS: International Nonproprietary Name: Topiramate indications: Epilepsy; Generalised tonic-clonic seizures; Seizures in Lennox-Gastaut syndrome; Prophylaxis of Migraine headache innovator: Ortho-McNeil (Topamax); Janssen (Topamax) COUNTRY COVERAGE: Albania Australia Austria ...

Jul, 2014
Tolterodine - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Tolterodine indications: Urinary frequency, urgency and incontinence innovator: Pharmacia (Detrol, Detrusitol) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Tofacitinib - Comprehensive patent search US$ 7,500.00

... and results THIS REPORT COVERS: International Nonproprietary Name: Tofacitinib indications: In combination with Methotrexate, or other non-biological disease-modifying anti-rheumatic drugs for the treatment of moderate to severe active rheumatoid arthritis innovator:Roche (RoActemra, Actemra) COUNTRY ...

Jul, 2014
Tigecycline - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of ... Nonproprietary Name: Tigecycline indications: Complicated skin and skin structure infections; Complicated intra-abdominal infections innovator: Wyeth(Tygacil) COUNTRY COVERAGE: ...

Jul, 2014
Ticagrelor - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results THIS REPORT COVERS: International Nonproprietary Name: Ticagrelor indications: Prevention of thrombotic events in a patient with acute coronary syndromes, optionally in combination with Aspirin innovator: AstraZeneca (Brilinta, Possia, Brilique) COUNTRY COVERAGE: Australia Canada France ...

Jul, 2014
Ticagrelor - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results THIS REPORT COVERS: International Nonproprietary Name: Ticagrelor indications: Prevention of thrombotic events in a patient with acute coronary syndromes, optionally in combination with Aspirin innovator: AstraZeneca (Brilinta, Possia, Brilique) COUNTRY COVERAGE: Albania Australia Austria ...

Jul, 2014
Ticagrelor - Comprehensive patent search US$ 7,500.00

... results THIS REPORT COVERS: International Nonproprietary Name: Ticagrelor indications: Prevention of thrombotic events in a patient with acute coronary syndromes, optionally in combination with Aspirin innovator:AstraZeneca (Brilinta, Possia, Brilique) COUNTRY COVERAGE: The In-depth search contains ...

Jul, 2014
Temsirolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Temsirolimus indications: Advanced renal cell carcinoma. innovator: Wyeth (Torisel) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Telmisartan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Telmisartan indications: Hypertension innovator: Boehringer Ingelheim (Micardis, Micardis HCT, Micardis Plus, Pritor) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Tamsulosin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Tamsulosin indications: Benign prostatic hyperplasia; Urinary disorders innovator: Boehringer Ingelheim (Flomax); Yamanouchi (Flomax); CSL (Flomax) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina ...

Jul, 2014
Tadalafil - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Tadalafil indications: Male erectile dysfunction, Impotence innovator: Lilly (Cialis) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Tacrolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Tacrolimus indications: Immunosuppressant; Eczema innovator: Fujisawa (Prograf, Protopic); Janssen-Cilag (Prograf) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria ...

Jul, 2014
Sunitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Sunitinib indications: Gastrointestinal stromal tumour; advanced renal cell carcinoma innovator: Pfizer(Sutent) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada ...

Jul, 2014
Sugammadex - Comprehensive patent search US$ 7,500.00

... and results THIS REPORT COVERS: International Nonproprietary Name: Sugammadex indications: Reversal of neuromuscular blockade induced by Rocuronium or Vecuronium innovator:Organon (Bridion); Merck (Bridion) COUNTRY COVERAGE: The In-depth search contains patents from territories that are individually ...

Jul, 2014
Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... : Sitagliptin indications: Improvement of glycemic control in patients with type 2 diabetes mellitus; used alone or in combination with Metformin or a PPARy agonist. innovator: Merck ...

Jul, 2014
Simvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Simvastatin indications: Hypercholesterolemia, Hyperlipidemia innovator: Merck (Zocor, Lipex, Simvar) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada ...

Jul, 2014
Silodosin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Silodosin indications: Benign prostatic hypertropy innovator: Kissei (Urief); Watson (Rapaflo) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Sildenafil - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Sildenafil indications: Male erectile dysfunction; pulmonary arterial hypertension, angina innovator: Pfizer (Viagra, Revatio) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil ...

Jul, 2014
Saxagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... THIS REPORT COVERS: International Nonproprietary Name: Saxagliptin indications: Treatment of type 2 diabetes mellitus optionally in combination with Metformin, a sulphonylurea or a thiazolidinedione innovator: Bristol-Myers Squibb (Onglyza, Kombiglyze); AstraZeneca (Onglyza) COUNTRY COVERAGE: Albania ...

Jul, 2014
Saxagliptin - Comprehensive patent search US$ 7,500.00

... THIS REPORT COVERS: International Nonproprietary Name: Saxagliptin indications: Treatment of type 2 diabetes mellitus optionally in combination with Metformin, a sulphonylurea or a thiazolidinedione innovator:Bristol-Myers Squibb (Onglyza, Kombiglyze); AstraZeneca (Onglyza) COUNTRY COVERAGE: The In- ...

Jul, 2014
Rosuvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... THIS REPORT COVERS: International Nonproprietary Name: Rosuvastatin indications: Hyperlipidemia; Mixed Dyslipidemia; Hypertriglyceridemia; Homozygous Familial Hypercholesterolemia; Atherosclerosis innovator: AstraZeneca (Crestor, Visacor) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia ...

Jul, 2014
Rosiglitazone - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Rosiglitazone indications: Type 2 diabetes mellitus innovator: GSK (Avandia, Avaglim, Avandamet); SB Pharmco (Avandia, Avandaryl, Avandamet) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil ...

Jul, 2014
Ropinirole - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... searches and results THIS REPORT COVERS: International Nonproprietary Name: Ropinirole indications: Parkinson's disease; restless legs syndrome innovator: GlaxoSmithKline (Requip, Repreve, Adartrel, Ardentel and Vunexin ) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina ...

Jul, 2014
Rizatriptan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Add your own notes, save searches and results THIS REPORT COVERS: International Nonproprietary Name: Rizatriptan indications: Treatment of acute migraine attacks innovator: Merck (Maxalt) COUNTRY COVERAGE: Albania Australia Austria Belgium Bosnia & Herzegovina Brazil Bulgaria Canada China ...

Jul, 2014
Rivastigmine - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... basis SAVE VAST AMOUNTS OF TIME Complete, reliable and verifiable data so you don’t have to fill holes and double check Intelligent, ... registers is provided at no additional charge. ABOUT GENERICSWEB: Patent, Extension and Data Exclusivity Expiry Snapshot is just one of the benchmark products from ...

Jul, 2014
Rivaroxaban - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... Nonproprietary Name: Rivaroxaban indications: Prevention of venous thromboembolism in adult patients who are undergoing elective hip or knee replacement surgery or who have undergone major orthopaedic surgery of the lower limps; Deep vein thrombosis; Pulmonary embolism innovator: Bayer ...

Jul, 2014
1 2 3 4 5 >
Skip to top